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were extracted and summarized. RESULTS: The study identi-
ﬁed 16 adverse events associated with blood transfusions in
which incidence rates were reported in the literature for the
time period of 2000 to 2007. Of those, the adverse events with
the highest associated mortality rate were: 1) acute haemolytic
transfusion reactions due to non-ABO compatibility (between
2.11%–7.06%); 2) transfusion-related acute lung injuries
(TRALI) (10% approx); and 3) bacterial sepsis (between 17%–
22%). Reported as incidence rates, the most frequently
reported adverse event was febrile reaction (0.9/1000 by trans-
fusion units) and mild allergic reaction (1/50–1/100 by trans-
fusion units). CONCLUSION: In spite of today’s safety and
quality controls measures for blood transfusions, a considerable
risk of adverse events is still associated with them. Therefore,
alternatives to blood transfusions should be considered when
possible.
HEMATOLOGICAL DISORDERS—Cost Studies
PHM2
BUDGET IMPACT (BI) OF PARENTERAL IRONTREATMENT OF
IRON DEFICIENCY ANAEMIA (IDA) IN SWITZERLAND
Steiner S1, Brock E1, Schneider H1, Ruckdaeschel S1,Troxler J2,
Rohrbacher R1
1HealthEcon Ltd, Basel, Switzerland, 2Vifor Ltd. Pharmaceutical
Specialties,Villars-sur-Glâne, Switzerland
OBJECTIVES: IDA, the most common form of anaemia, has a
relatively high prevalence across Europe. IDA is common in
pregnancy, postpartum and inﬂammatory bowel disease (IBD)
with IDA prevalences of 18, 17 and 33% respectively. At
present, treatment with parenteral iron substitution is limited
by the amount of iron which can be administered intravenously
in any one application. This study estimates the BI associated
with partially substituting the standard i.v. treatment, iron
sucrose, with a new treatment, ferric carboxymaltose, allowing
for the application of higher dosages in a shorter time. The
study adopted the perspective of the Swiss mandatory health
insurance over 3 years covering the indications pregnancy, post-
partum and IBD. METHODS: Resource use was based on
primary data and guidelines. Costs were estimated using a fee-
for-service reimbursement system (Tarmed), including drug, per-
sonnel and other costs. The price of ferric carboxymaltose was
assumed to be that of iron sucrose +40%. The BI was estimated
for the ﬁrst 3 years post-launch, using a substitution rate of
20% in year 1 and 50% in year 2 and 3. RESULTS: Ferric
carboxymaltose reduces the costs per treatment cycle and
patient in IBD by 35% compared to iron sucrose (CHF 475 vs.
CHF 732), due to reduced personnel costs: 1000 mg iron
requires one application with ferric carboxymaltose and 5 for
iron sucrose (200 mg each). Total savings to the Swiss manda-
tory health insurance amount to approx. CHF 1 Mio (approx.
€ 611′600) in year 1 and approx. CHF 2.5 Mio in year 2 and
3 each. Costs were also reduced by 33% in the gynaecological
indication using smaller, empirical dosages of 500 mg. CON-
CLUSION: Treating IDA involves substantial costs to the Swiss
mandatory health insurance. Substitution of iron sucrose by
ferric carboxymaltose may help to reduce these due to saved
personnel costs, despite higher product costs.
PHM3
CLINICO-ECONOMICAL ANALYSIS OF BORTEZOMIBVS
DEXAMETHASONE IN RECURRENT ORTREATMENT-
RESISTANT MULTIPLE MYELOMA IN RUSSIA
Avksentieva M1,Vorobiev P2
1Moscow Medical Academy named after M.I.Sechenov, Moscow,
Moscow, Russia, 2Moscow Medical Academy named after
M.I.Sechenov, Moscow, Russia
OBJECTIVES: To analyze cost-effectiveness of bortezomib
versus dexamethasone for recurrent or treatment-resistant mul-
tiple myeloma in Russian health care system. METHODS: The
study was performed from the Russian reimbursement system
point of view. An economic model prepared for the submission to
National Institute of Health and Clinical Excellence was used as
a framework. Effect of studied drugs was measured in life-years
gained. The effectiveness was estimated on the basis of APEX
study results and complemented with prognosis of long-term
outcomes. Direct medical costs for medication were included into
the model, registered prices were taken from the Russian reim-
bursement list while dose regimen and number of treatment
courses were considered to be equal to those used in APEX study.
The incremental cost-effectiveness ratio (CER) was calculated.
RESULTS: The incremental effectiveness of bortezomib versus
dexamethasone was estimated as 2,371–2,739 life-years gained
(the interval includes minimal and maximal values identiﬁed by
different approaches to long-term outcomes projection). The
incremental cost was 1 822 774,00 rubles (about 70 thousands
USD). The incremental CER was 67,510,148 — 792,510,43
rubles (25–29 thousands USD) per life-year gained. CONCLU-
SION: The incremental CER for bortezomib is comparable with
other expensive drugs included into the reimbursement system.
Further studies are needed to assess cost-effectiveness of bort-
ezomib vs other therapeutic strategies used for resistant and
recurrent multiple myeloma and to evaluate effectiveness in
medical practice.
PHM4
CLINICO-ECONOMICAL ANALYSIS OF FERRUM LEKVS
FENULS IN IRON-DEFICIENT ANEMIA IN ELDERLY PATIENTS
Vorobiev P, Nekrasova N, Dorkina A, Sura M
Moscow Medical Academy named after I.M.Sechenov, Moscow, Russia
OBJECTIVES: To analyze cost-effectiveness of Ferrum Lek
(Ferrum III) versus Fenuls (Ferrum II) for iron-deﬁcient anemia in
elderly patients with gastrointestinal comorbidy in Russian
health care system. METHODS: Randomized multi-center
study of 132 ambulatory patients (60–86 years old, mean age
69.11  6.39; 102 (77.27%) were females). Criteria for anemia
was decreasing of hemoglobin (Hb) level below 110 g/L. Sixty-
six patients received either Ferrum Lek (200 mg daily) or Fenuls
(200 mg daily). Duration of treatment was 6 weeks. Criteria of
effectiveness were: normalization of Hb level; increasing levels
of Hb and Fe in plasma; adverse effects at day 42 after start
of treatment. The cost-effectiveness ratio (CER) was calculated
(cost of 1 g/L Hb increasing). RESULTS: At follow-up Hb level
increases in Ferrum Lek group was 30.1 g/L (12.3–88.4) and
19.8 g/L (4–39) in Fenuls group. Normalization of Hb level
(110 g/L) was achieved in 62 (93.94%) patients in Ferrum Lek
group and in 53 (80.3%) patients in Fenuls group. Targeted Hb
level (120 g/L) was achieved in 54 (81.82%) patients in Ferrum
Lek group and in 36 (54.55%) patients in Fenuls group. Drop-
outs due to adverse effects were: 1 patient in Ferrum Lek group
and 9 patients in group. Gastrointestinal adverse effects occurred
signiﬁcantly more often in Fenuls group than in Ferrum Lek
group (constipation in 21.2% and 1.5% patients, gastric com-
plaints in 28.8% and 6% respectively). The cost per achieving
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